S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
NASDAQ:LPTX

Leap Therapeutics (LPTX) Stock Price, News & Analysis

$2.83
+0.04 (+1.43%)
(As of 03/1/2024 ET)
Today's Range
$2.82
$3.00
50-Day Range
$2.44
$4.78
52-Week Range
$1.24
$10.20
Volume
221,607 shs
Average Volume
204,472 shs
Market Capitalization
$72.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.13

Leap Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
399.1% Upside
$14.13 Price Target
Short Interest
Bearish
4.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Leap Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.10) to ($2.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.85 out of 5 stars

Medical Sector

514th out of 952 stocks

Pharmaceutical Preparations Industry

234th out of 432 stocks


LPTX stock logo

About Leap Therapeutics Stock (NASDAQ:LPTX)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

LPTX Stock Price History

LPTX Stock News Headlines

LPTX Mar 2024 7.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
LPTX Jun 2024 1.000 call
LPTX Mar 2024 1.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Recap: Leap Therapeutics Q3 Earnings
Leap Therapeutics (LPTX) Receives a Buy from H.C. Wainwright
Leap Therapeutics (LPTX) Receives a Buy from Raymond James
See More Headlines
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/02/2024
Next Earnings (Estimated)
3/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.13
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+399.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-54,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$5.94 per share

Miscellaneous

Free Float
22,676,000
Market Cap
$72.35 million
Optionable
Optionable
Beta
0.59
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Douglas E. Onsi J.D. (Age 55)
    CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
    Comp: $1.04M
  • Mr. Augustine J. Lawlor (Age 67)
    Chief Operating Officer
    Comp: $713.57k
  • Dr. Cynthia A. Sirard (Age 54)
    Chief Medical Officer
    Comp: $708.64k
  • Dr. Jason S. Baum Ph.D. (Age 45)
    Chief Scientific Officer
  • Mr. Mark O'Mahony (Age 53)
    Chief Manufacturing Officer
  • Ms. Christine M. Granfield (Age 56)
    VP and Head of Regulatory Affairs & Quality














LPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings
or view top-rated stocks.

What is Leap Therapeutics' stock price target for 2024?

4 brokers have issued 1-year price objectives for Leap Therapeutics' shares. Their LPTX share price targets range from $7.00 to $20.00. On average, they predict the company's stock price to reach $14.13 in the next year. This suggests a possible upside of 399.1% from the stock's current price.
View analysts price targets for LPTX
or view top-rated stocks among Wall Street analysts.

How have LPTX shares performed in 2024?

Leap Therapeutics' stock was trading at $4.15 on January 1st, 2024. Since then, LPTX stock has decreased by 31.8% and is now trading at $2.83.
View the best growth stocks for 2024 here
.

Are investors shorting Leap Therapeutics?

Leap Therapeutics saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 1,120,000 shares, an increase of 74.8% from the January 31st total of 640,800 shares. Based on an average daily volume of 281,500 shares, the days-to-cover ratio is currently 4.0 days. Currently, 4.8% of the company's shares are sold short.
View Leap Therapeutics' Short Interest
.

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024.
View our LPTX earnings forecast
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) released its earnings results on Monday, November, 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.07.

When did Leap Therapeutics' stock split?

Leap Therapeutics shares reverse split before market open on Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Leap Therapeutics own?
Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.60%), Key Client Fiduciary Advisors LLC (0.84%), Price T Rowe Associates Inc. MD (0.47%), Price T Rowe Associates Inc. MD (0.47%), Northern Trust Corp (0.17%) and Simplex Trading LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LPTX) was last updated on 3/2/2024 by MarketBeat.com Staff